Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2010

01-12-2010 | Letter to the Editor

Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?

Authors: Ali Alkan, Ugur Sahin, Kadri Altundag

Published in: Medical Oncology | Issue 4/2010

Login to get access

Excerpt

To The Editor, …
Literature
1.
Polyzos A, Malamos N, Boukovinas I, et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat. 2009. Published online: Jul 28 [Epub ahead of print].
2.
Earl HM, Vallier A, Hiller L, et al. Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide of E/C and paclitaxel ± gemcitabin in the treatment of high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol. 2009;27:15s (suppl; abstr 522).
3.
Taghian AG, Abi-Raad R, Assaad SI, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol. 2005;23:1951–61.CrossRefPubMed
Metadata
Title
Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?
Authors
Ali Alkan
Ugur Sahin
Kadri Altundag
Publication date
01-12-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9322-9

Other articles of this Issue 4/2010

Medical Oncology 4/2010 Go to the issue

Original Paper

The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study

Original Paper

The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment

Original Paper

Apoptosis of human colorectal carcinoma cells is induced by blocking hepatoma-derived growth factor

Original Paper

Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era

Original Paper

Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication

Original Paper

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits